Medscape Conference Coverage, based on selected sessions at the:

American Society of Hematology (ASH) 49th Annual Meeting and Exposition

December 08 - 11, 2007; Atlanta, Georgia

This activity is not sanctioned by, nor a part of, the American Society of Hematology.

Expert Interview

  • An Expert Interview With Dr. Brian Druker

    Functional approaches in development may enable physicians to rapidly identify factors that are important for the growth and survival of a particular leukemia and would serve as targets for therapy.
  • New Therapeutic Options in CML

    In this Expert Interview from ASH 2007, Dr. Jorge Cortes discusses new and follow-up data from clinical trials of drug therapies for CML.

Conference News

  • Intensive Regimen in Mantle Cell Lymphoma

    An intensive immunochemotherapy regimen used in a Nordic study shows a plateau in survival curves that suggest a cure is in sight, say researchers.
  • Oblimersen with Chemotherapy for Relapsed CLL

    The addition of the antisense agent oblimersen to fludarabine and cyclophosphamide improved response to therapy and survival in patients with relapsed or refractory chronic lymphocytic leukemia.
  • Bortezomib and Remission in Multiple Myeloma

    Adding bortezomib to standard induction therapies in patients with newly diagnosed multiple myeloma improves complete remission rates.
  • Mutation in ALL in Children with Down Syndrome

    Mutations in the JAK2 gene appear to be associated with nearly 20% of cases of acute lymphoblastic leukemia in children with Down syndrome.
  • Vaccine Improves Survival in Myeloid Leukemia

    An experimental peptide vaccine produced an immunologic response in more than half of study participants and was associated with longer event-free survival and periods of remission.
  • Improving Survival in Pediatric Ph-Positive ALL

    Combining a tyrosine kinase inhibitor with intensive chemotherapy doubled the survival rate in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • Plerixafor: Stem Cell Harvests for Transplantation

    A novel product mobilizes stem cells quickly and increases the yield, making stem cell transplantation a viable option for more patients.
  • Complete Remission in AML with Lintuzuma

    An experimental antibody produced complete remissions in elderly patients with acute myeloid leukemia.
  • Standard Care in Advanced Hodgkin's Lymphoma

    New results with an escalated chemotherapy regimen challenge the standard treatment for advanced-stage Hodgkin's lymphoma.
  • Rivaroxaban VTE Prevention

    Two phase 3 trials with the new oral anticoagulant rivaroxaban suggest it is more effective than enoxaparin in preventing venous thromboembolism in patients undergoing major orthopedic surgery.
  • Umbilical Cord Blood for Older Patients

    Umbilical cord blood can be an alternative graft source for older patients in need of a hematopoietic stem cell transplant, but who lack an HLA-matched related donor.
  • Zevalin Improves Progression-Free Survival in Follicular Lymphoma

    Dramatic results showing that radioimmunotherapy with Zevalin prolongs progression-free survival by 2 years come just days after cuts in reimbursement for this therapy were announced in the United States.
  • Prolonging Survival in Myelodysplastic Syndrome

    For the first time, a significant prolongation of survival has been seen in this disorder, leading to calls for azacitidine to be offered to all high-risk patients.
  • Survival Benefit With Low-Dose Dexamethasone in Multiple Myeloma

    Using low-dose dexamethasone with lenalinomide instead of high-dose dexamethasone in newly diagnosed multiple myeloma patients confers a significant survival advantage and has less toxicity.
  • Dasatinib Effective in CML Patients Resistant to Imatinib

    At 2-year follow-up, dasatinib continued to demonstrate efficacy and prolong survival among patients with chronic myelogenous leukemia who are either intolerant or resistant to treatment with imatinib.
  • Agent Shows Efficacy in Relapsed NHL and CLL

    Bendamustine induced a higher rate of response in patients with relapsed indolent non-Hodgkin's lymphoma and had better clinical outcomes in patients with chronic lymphocytic leukemia than chlorambucil.
  • Recombinant IL-2 Benefits AML Patients

    Preliminary data suggest that rIL-2 may be of therapeutic benefit in younger AML patients who have completed therapy and entered their first remission.

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Hematology. These materials and the related activity are not sanctioned by the American Society of Hematology or the commercial supporter of the conference and do not constitute an official part of that conference.